An inhibitor designed to block a protein linked to cancer initially encounters a physical barrier within its target. Then, instead of bouncing back, it forces the target to deform in order to accommodate it. This is the scenario documented by researchers at the University of Tübingen and the University of Buffalo, in a study published in Angewandte Chemie International Edition.
A square does not normally fit into a circle. But what happens if the square can alter the shape of the hole? That is exactly what a new drug molecule can do when it binds to its target protein, according to the study published on September 15. The target in question is called p38 delta, a kinase involved in several tumor processes.
- A drug molecule induces deformation of the p38 delta protein around it rather than being rejected.
- The “bump-kink” mechanism boosts selectivity by 12,000-fold and potency by 110-fold compared with existing compounds.
- This discovery enables inhibitors that are specific to a single kinase variant, reducing adverse effects.
A Collision That Should Have Blocked Everything
The molecule, an inhibitor designed to block the protein’s activity, initially collided with a flexible loop within the structure of p38 delta. In the conventional logic of drug design, this kind of steric clash is disqualifying. A molecule that is too bulky for the pocket it targets usually ends up in the discard pile of candidate drugs, weeded out during screening.
Nothing like that happened here.
That impact should have hindered binding. Instead, it forced the loop to change shape and coil around the molecule, creating a particularly tight fit. The quantified result speaks for itself: the molecule achieved a 12,000-fold improvement in selectivity for p38 delta and proved 110-fold more potent than compounds available up to now. For a medicinal chemist, such gains on a single molecule are almost never a product of chance.
The “Bump-Kink,” a Lock That Learns to Bend
The story begins far from the crystallography lab. The first author, Nico J. Seidler, synthesized several molecules intended to bind these kinases during his PhD in Laufer’s lab at the University of Tübingen. Among these compounds, only one stood out. A molecule distinguished itself by exceptional selectivity for p38 delta, though the reason remained unclear.
The answer came from a stay in the United States. Having become a Fulbright fellow in Heppner’s laboratory in Buffalo, Seidler conducted structural studies on this molecule. The technique used, X-ray crystallography, allows photographing the atomic arrangement of a fixed protein bound to its inhibitor, frame by frame, until its exact geometry is reconstructed.
The pictures revealed that the molecule induced a shape change in p38 delta around it. The researchers called this phenomenon the “bump-kink,” literally the “bend that folds.” A portion of the molecule collides with the protein’s flexible loop, causing it to bend; this bend brings the loop closer to another part of the molecule, enabling the protein to coil, or self-encapsulate, around it.
In short, a lock that twists to embrace its own key, so to speak.
Why This Deformation Changes the Game for Future Treatments
Most kinase inhibitors operate on a rigid model: one seeks a molecule whose shape fits perfectly into an existing pocket, much like selecting a key for a pre-made lock. The problem is that many kinases in the p38 family bear a strong resemblance to one another. An inhibitor tailored for p38 delta often tends to affect p38 alpha or p38 gamma as well, bringing with it adverse effects that are difficult to anticipate.
The bump-kink mechanism shifts the design logic. Instead of hunting for a key that fits on the first try, chemists can now exploit the natural flexibility of a protein loop to craft a lock tailored to a single protein variant. This strategy largely explains the pronounced increase in selectivity observed for this molecule.
Whether this principle can be generalized to other kinase families remains to be seen. The same teams are now exploring whether similar flexible loops exist in other therapeutic targets, with the hope of inducing the same kind of bespoke bending there.
Sources: pmc.ncbi.nlm.nih.gov | tonglab.biology.columbia.edu | nature.com
